Hospital Mae de Deus
Porto Alegre, Brazil
11 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled652 locationsNCT06424288
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled641 locationsNCT06935370
Recruiting
Phase 2
Study of Novel Treatment Combinations in Patients With Lung Cancer
Lung CancerAdvanced or Metastatic Non-small Cell Lung CancerResectable Non-small Cell Lung Cancer
Gilead Sciences270 enrolled100 locationsNCT05633667
Recruiting
Phase 3
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Lymphoma
Hoffmann-La Roche182 enrolled75 locationsNCT06084936
Recruiting
Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Breast Cancer
Pfizer1,020 enrolled518 locationsNCT06760637
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled189 locationsNCT04534205
Recruiting
Phase 3
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Multiple Myeloma
Pfizer492 enrolled273 locationsNCT06152575
Recruiting
Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Multiple Myeloma
Pfizer944 enrolled239 locationsNCT05020236
Recruiting
Not Applicable
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Prostate CancerCardiovascular Disease
McMaster University6,000 enrolled54 locationsNCT03127631